Edition:
United Kingdom

Pacific Biosciences of California Inc (PACB.OQ)

PACB.OQ on NASDAQ Stock Exchange Global Select Market

2.66USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
232,888
52-wk High
$5.73
52-wk Low
$2.62

Summary

Name Age Since Current Position

Michael Hunkapiller

68 2012 Chairman of the Board, President, Chief Executive Officer

Susan Barnes

63 2015 Chief Financial Officer, Executive Vice President, Principal Accounting Officer

Kathy Ordonez

66 2017 Executive Vice President and Chief Commercial Officer and Director

Kevin Corcoran

58 2012 Senior Vice President - Market Development

James Phillips

66 2010 Senior Vice President - Research and Development

William Ericson

58 2010 Lead Independent Director

David Botstein

72 2012 Independent Director

Brook Byers

71 2004 Independent Director

Randall Livingston

63 2009 Independent Director

John Milligan

55 2013 Independent Director

Marshall Mohr

61 2012 Independent Director

Lucy Shapiro

76 2012 Independent Director

Biographies

Name Description

Michael Hunkapiller

Dr. Michael W. Hunkapiller, Ph.D., serves as a Chairman of the Board, President, Chief Executive Officer of Pacific Biosciences of California, Inc. He became our President and Chief Executive Officer in 2012. He is Chairman of our Board of Directors, and has served on our Board of Directors since 2005. Since November 2004, Dr. Hunkapiller has been a General Partner at Alloy Ventures, or Alloy, a venture capital firm. Prior to Alloy, Dr. Hunkapiller spent 21 years at Applied Biosystems. At Applied Biosystems, he held various positions, most recently serving as president and general manager. Dr. Hunkapiller holds a Ph.D. in Chemical Biology from the California Institute of Technology and a B.S. in Chemistry from Oklahoma Baptist University.

Susan Barnes

Ms. Susan K. Barnes serves as a Chief Financial Officer, Executive Vice President, Principal Accounting Officer of Pacific Biosciences of California Inc. She joined us in 2010 as our Senior Vice President and Chief Financial Officer and was promoted to Executive Vice President and Chief Financial Officer in December 2010. From 1997 to 2005, she was senior vice president, finance and chief financial officer of Intuitive Surgical, Inc. Ms. Barnes served on several boards of directors of public and private companies, including Northstar Neuroscience, Inc. from February 2006 to December 2009, where she also served as Audit Committee chair, and RAE Systems from September 2004 to May 2006, where she served as chair of the Audit Committee. Ms. Barnes holds an A.B. from Bryn Mawr College and an M.B.A. from the Wharton School, University of Pennsylvania.

Kathy Ordonez

Ms. Kathy P. Ordonez serves as a Executive Vice President and Chief Commercial Officer and Director of Pacific Biosciences of California Inc. . Ordoñez has a 30 year history of leadership in the life sciences and diagnostics industries, including positions as Senior Vice President of Quest Diagnostics, Chief Executive Officer of Celera, founder of Celera Diagnostics, and President and Chief Executive Officer for Roche Molecular Systems. In 2011 Ordoñez joined Quest as part of its acquisition of Celera and was responsible for the company's Diagnostic Solutions businesses, including diagnostic products, life insurer services, clinical trials and healthcare information technology products until she retired in 2013. Previously, she managed Quest's innovation pipeline and diagnostic products businesses, led the Celera business (including Berkeley HeartLab) and was responsible for driving the company's focus on personalizing disease management through diagnostic products and services. Prior to the acquisition by Quest, Ordoñez served as Chief Executive Officer of Celera and was a founder of Celera Diagnostics. Before joining Celera's parent company, Applera, in December 2000, Ordoñez held a number of senior positions over a 15-year period with Hoffmann-La Roche. She oversaw the formation of Roche Molecular Systems, serving as President and Chief Executive Officer, and led the application of polymerase chain reaction technology to the diagnostic, research and forensic fields.

Kevin Corcoran

Mr. Kevin Corcoran serves as a Senior Vice President - Market Development of Pacific Biosciences of California Inc. He joined us in 2007 as our Vice President of software and informatics development. In March 2011 Mr. Corcoran was promoted to Senior Vice President and was responsible for all systems related development for the PacBio RS SMRT Sequencing System, and in March 2012, he became our Senior Vice President of Market Development and is responsible for overall management of developing and increasing market opportunities for our current and future products. Mr. Corcoran served as President and CEO of Lynx Therapeutics from 2002 to 2004 where he was responsible for the development and commercialization of a massively parallel short read sequencing technology. While at Lynx, Mr. Corcoran jointly acquired with Solexa management the DNA cluster amplification technology, which is now a key component of Illumina’s sequencing platforms. From 2004 to 2007, Mr. Corcoran served as Vice President and General Manager of Applied Biosystems DNA sequencing business, a global business with over $600M dollars in annual sales. While at ABI, Mr. Corcoran managed the teams responsible for the commercial development and deployment of SOLiD. Mr. Corcoran holds a B.S. in Computer Science from California State University, Hayward.

James Phillips

Mr. James Michael Phillips serves as a Senior Vice President - Research and Development of Pacific Biosciences of California Inc. He joined us in 2005 as our Vice President of Product Development and since February 2010, has served as our Senior Vice President of Research and Development. Prior to joining us, Mr. Phillips held various management roles at Applied Biosystems spanning research and development test, manufacturing operations and service support from 1986 to April 2005. His most recent position at Applied Biosystems was Senior Director, Research and Development. Mr. Phillips earned a B.S. in Bacteriology from the University of California, Davis.

William Ericson

Mr. William Ericson, J.D.., serves as a Lead Independent Director of Pacific Biosciences of California Inc. Mr. Ericson is a Managing Partner at Mohr Davidow Ventures, or MDV, a venture capital firm. He joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur and investor, and has led MDV’s focus on personalized medicine investing since 2003. Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law.

David Botstein

Dr. David Botstein, Ph.D., serves as an Independent Director of Pacific Biosciences of California, Inc. Effective January 2014, Dr. Botstein is the Chief Scientific Officer at Calico Life Sciences. Dr. Botstein was formerly Director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University, where he served from 2003 to 2013. From 1990 to 2003 he was Chairman of the Department of Genetics at Stanford University. Previously, he was Vice President for Science at Genentech, and today serves on Genentech’s Scientific Resource Board. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Dr. Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.

Brook Byers

Mr. Brook H. Byers, Ph.D., serves as an Independent Director of Pacific Biosciences of California Inc. Mr. Byers has been a venture capital investor since 1972 and is a Managing Partner of Kleiner Perkins Caufield & Byers. He has been closely involved with more than 50 new technology-based ventures, many of which have already become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led Kleiner Perkins Caufield & Byers to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. Mr. Byers served on the board of directors of Genomic Health, Inc. from 2001 to 2011 and currently serves on the board of directors of Foundation Medicine and Veracyte. Mr. Byers holds a B.S. degree in Electrical Engineering from the Georgia Institute of Technology and an M.B.A from Stanford University.

Randall Livingston

Mr. Randy Livingston serves as an Independent Director of Pacific Biosciences of California Inc. He has served as Vice President for Business Affairs and Chief Financial Officer of Stanford University since March 2001. Before joining Stanford, Mr. Livingston served as the executive vice president, chief financial officer and a director of OpenTV Corp. from 1999 to 2001. Before joining OpenTV in 1999, Mr. Livingston served as a consultant and part-time chief financial officer for Silicon Valley technology companies with such diverse specialties as genomics, Internet commerce, medical devices, chemical synthesis and enterprise software. Previously, he was director of corporate development at Apple Computer and chief financial officer for Taligent, a 400-employee Apple-IBM-Hewlett-Packard joint venture system software company. Mr. Livingston currently serves as a director of Genomic Health, Inc. and eHealth, Inc. Mr. Livingston holds a B.S. in Mechanical Engineering and an M.B.A. from Stanford University.

John Milligan

Dr. John F. Milligan, Ph.D., serves as an Independent Director of Pacific Biosciences of California, Inc. Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer of Gilead. He was named Gilead’s Chief Operating Officer in 2007 and President in 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University. Dr. Milligan received his BA from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

Marshall Mohr

Mr. Marshall L. Mohr serves as an Independent Director of Pacific Biosciences of California, Inc. Since March 2006, he has been Senior Vice President and Chief Financial Officer of Intuitive Surgical, Inc., a provider of surgical robotics. Prior to joining Intuitive Surgical, Mr. Mohr served as Vice President and Chief Financial Officer of Adaptec, Inc. Before 2003, Mr. Mohr was an audit partner with PricewaterhouseCoopers LLP where he was most recently the managing partner of the firm’s West Region Technology Industry Group and led its Silicon Valley accounting and audit advisory practice. Since 2005, Mr. Mohr has been a member of the board of directors and chairman of the audit committee of Plantronics, Inc., a provider of lightweight communications headsets and telephone headset systems, and also served as a member of the board of directors and chairman of the audit committee of Atheros Communications, Inc., a developer of semiconductor system solutions for wireless communications products, from November 2003 to May 2011 when Atheros was sold to Qualcomm, Inc. Mr. Mohr holds a Bachelor of Business Administration in Accounting and Finance from Western Michigan University.

Lucy Shapiro

Dr. Lucy Shapiro, Ph.D., serves as an Independent Director of Pacific Biosciences of California, Inc. Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006. Dr. Shapiro was also a director of Gen-Probe, Inc. from 2008 to 2012.

Basic Compensation

Name Fiscal Year Total

Michael Hunkapiller

1,985,160

Susan Barnes

1,240,720

Kathy Ordonez

143,528

Kevin Corcoran

954,458

James Phillips

954,458

William Ericson

210,250

David Botstein

181,250

Brook Byers

186,250

Randall Livingston

196,250

John Milligan

193,250

Marshall Mohr

193,250

Lucy Shapiro

591,250
As Of  31 Dec 2016